ASH 2020 | Thiotepa-containing regimens for PCNSL patients undergoing autoHCT

Trent Wang, DO, MPH, Sylvester Comprehensive Cancer Center, Miami Springs, FL, discusses the role of thiotepa-containing conditioning regimens in patients with primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) who are undergoing autologous hematopoietic cell transplantation (autoHCT). Primary CNS lymphoma (PCNSL) is a rare non-Hodgkin lymphoma, and no studies have been conducted to determine the optimal conditioning regimen for these patients. Thiotepa plus busulfan and cyclophosphamide (TBC), thiotepa plus carmustine (TT-BCNU), and BCNU/etoposide/cytarabine/melphalan (BEAM) are common regimens, so a retrospective analysis of over 600 patients was carried out to compare outcomes for PCNSL patients receiving these treatments. When 3-year progression free survival was investigated, TBC and TT-BCNU were found to give superior results to BEAM. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.